Biothera takes over Antisoma anticancer compound
In future, Biothera is planning to conduct trials with the combination therapy of Imprime PGG and AS1402. Imprime PGG is a new immunotherapy that works synergistically with anti-tumor
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.